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https://doi.org/10.1016/j.immuni.2020.06.002SUMMARYDendritic cells (DCs) are antigen-presenting cells controlling T cell activation. In humans, the diversity,
ontogeny, and functional capabilities of DC subsets are not fully understood. Here, we identified circulating
CD88CD1c+CD163+ DCs (called DC3s) as immediate precursors of inflammatory CD88CD14+CD1c+
CD163+FcεRI+ DCs. DC3s develop via a specific pathway activated by GM-CSF, independent of cDC-
restricted (CDP) and monocyte-restricted (cMoP) progenitors. Like classical DCs but unlike monocytes,
DC3s drove activation of naive T cells. In vitro, DC3s displayed a distinctive ability to prime CD8+ T cells ex-
pressing a tissue homing signature and the epithelial homing alpha-E integrin (CD103) through transforming
growth factor b (TGF-b) signaling. In vivo, DC3s infiltrated luminal breast cancer primary tumors, and DC3
infiltration correlated positively with CD8+CD103+CD69+ tissue-resident memory T cells. Together, these
findings define DC3s as a lineage of inflammatory DCs endowed with a strong potential to regulate tumor im-
munity.INTRODUCTION
Human dendritic cells (DCs) are sentinel cells of the immune sys-
tem specialized in controlling T cell function (Banchereau and
Steinman, 1998; Palucka and Banchereau, 2013; Steinman
et al., 2003). The mouse model has brought important concepts
to our understanding of DCs and suggests that multiple DC sub-
sets arising from specialized ontogenetic pathways are en-
dowed with specific immune functions (Brisen˜o et al., 2016;
Guermonprez et al., 2019; Merad et al., 2013; Murphy
et al., 2016).
Definition of human DC subsets is a prerequisite to under-
standing the division of labor underpinning induction of various
types of immune responses. At homeostasis, conventional
DCs (cDCs) include cDC1s (CD141+XCR1+CLEC9A+IRF8+) and
cDC2s (CD1c+CD11c+CD172a+IRF4+) (Bachem et al., 2010;Immunity 53, 1–18, A
This is an open access article undCrozat et al., 2010; Heidkamp et al., 2016; Jongbloed et al.,
2010; Schlitzer et al., 2013). cDC1s and cDC2s arise through a
specialized ontogenetic pathway from a common DC precursor
(CDP) (Lee et al., 2015b) or from early IRF8+ multipotent lympho-
myeloid progenitors (MLPs) (Helft et al., 2017; Lee et al., 2017).
Bone marrow progenitors for cDCs generate a common circu-
lating precursor that progressively diverges into pre-cDC1 and
pre-cDC2 (Breton et al., 2015, 2016; See et al., 2017). This is
further complicated by inclusion of AXL+SIGLEC6+CD11c+
CD1c+ cells (AS-DCs also called type 5 DCs), which have been
proposed to act as precursors for cDCs (pre-cDCs) or a lineage
on its own (See et al., 2017; Villani et al., 2017).
An additional layer of complexity in the DC network lies in
its responsiveness to perturbations. For instance, inflammation
affects hematopoiesis and phagocyte trafficking, resulting in
leukocyte mobilization and tissue infiltration. Specifically,ugust 18, 2020 ª 2020 The Author(s). Published by Elsevier Inc. 1
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
(legend on next page)
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CD14+CD1c+ DCs, called inflammatory DCs (iDCs) (Binnewies
et al., 2019; Granot et al., 2017; Segura et al., 2012, 2013; Wol-
lenberg et al., 1996; Zaba et al., 2009). The expression of
CD1c lectin is shared between iDCs and cDCs. However,
CD1c+ iDCs also express multiple monocytic markers, such as
CD14, CCR2, and FcgRI/CD64. iDCs have been reported in in-
flamed skin, synovial fluid, ovarian cancer ascites, solid tumor in-
filtrates, and lymph nodes (Bakdash et al., 2016; Binnewies et al.,
2019; Granot et al., 2017; Lavin et al., 2017; Segura et al., 2012,
2013; Wollenberg et al., 1996; Zaba et al., 2009). The develop-
mental pathway of human CD1c+CD14+ iDCs is poorly under-
stood. In vitro studies suggest that iDCs obtained after
differentiation of CD14+ monocytes in granulocyte macrophage
colony-stimulating factor (GM-CSF) and interleukin-4 (IL-4) (Sal-
lusto and Lanzavecchia, 1994) might correspond to in vivo
iDCs (Granot et al., 2017; Segura et al., 2012, 2013). In this
context, IL-4 acts through induction of the transcriptional regu-
lator NCOR2 (Sander et al., 2017). In addition, triggering the
aryl hydrocarbon receptor in monocytes supports activation of
IRF4-dependent differentiation of iDCs (Goudot et al., 2017).
Together, these studies support the prevailing notion that
CD14+ monocytes act as immediate precursors for iDCs.
Re-evaluation of circulating mononuclear phagocyte diversity
has been enabled by single-cell RNA sequencing (scRNA-seq).
Recent studies have revealed that a subset of DC-like cells,
called DC3s, express mRNA for the CD14 and CD1c genes (Vil-
lani et al., 2017). However, this analysis was performed after
excluding cells expressing the highest amount of CD14 (Villani
et al., 2017). As a consequence, this approach renders a prob-
lematic distinction between DC3s and bona fide CD14+ mono-
cytes (Villani et al., 2017). This discrimination is further compli-
cated by previous reports of CD14+CD1c+ ‘‘inflammatory’’ DCs
recruited at inflammatory sites (Binnewies et al., 2019; Granot
et al., 2017; Segura et al., 2012, 2013; Wollenberg et al., 1996;
Zaba et al., 2009).Figure 1. DC3s Are a Discrete Subset of CD88–CD1c+CD163+ Cells in H
(A) Gating strategy used to define mononuclear phagocytes expressing CD14 and
from 3 healthy donors and pooled before scRNA-seq analysis. To improve the
(Figure S1A). Single cells were isolated using a droplet-based approach and se
dimensionality reduction (t-distributed stochastic neighbor embedding [tSNE]). C
clustering algorithm. Each dot represents an individual cell (n = 1,622).
(B) Hierarchal clustering of groups A, B, C, and D based on average gene expres
(C) Absolute number of differentially expressed genes (DEGs) for pairwise comp
(D) Heatmaps displaying relative expression of up to 20 DEGs defining each clus
(E) Violin plots illustrating expression probability distributions across clusters
expression of groups of genes (identified in violin plots) in each cell of the tSNE
(F) Expression distribution across clusters A, B, C, and D of gene signatures ident
way ANOVA test)
(G) Identification of 4 subsets within CD14lo to hi CD1clo to hi cells by unsupervis
unsupervised clustering were performed using the following markers: CD88, CD1
relative expression of each marker among the subsets. Dot plots (below) show t
dimensional analysis.
(H) Improved gating strategy for identification of cDC2s, DC3s, and CD14+ mono
FcεRI, CD5, CD14, CD116, and CD206.
(I) Principal-component analysis (PCA) for bulk-sequenced mononuclear phagoc
(J) Cluster dendrogram of the different cell types using the 2,000 most variable g
(K) Heatmaps comparing the relative expression of markers discriminating cluste
sorted subsets based on the gating strategy defined in (H) (right).
See also Figure S1 and Table S1.Here we intended to re-evaluate the definition of DC3s using
unbiased scRNA-seq and high-dimensional flow cytometry by
exploring the full spectrum of CD14 and CD1c expression. In
addition, we identify DC3 growth factor requirements and devel-
opmental pathways. Finally, we show that DC3s activate
CD103+ T cells and that DC3 infiltration in human breast tumors
correlates with the abundance of CD8+CD103+CD69+ tissue-
resident memory (TRM) T cells.
RESULTS
DC3s Represent a Discrete Subset of
CD88–CD1c+CD163+ Cells in Human Peripheral Blood
To probe the diversity of CD16CD141CD123 bloodmononu-
clear phagocytes, we developed a sorting strategy including all
phenotypic intermediates between CD14hiCD1clo and
CD14loCD1chi cells. The proportions between cell populations
were compensated to enrich in less abundant CD14loCD1chi
cells (Figure S1A). Flow cytometry-sorted cells isolated from
blood were analyzed using a droplet-based scRNA-seq
approach (Figure 1A; Figure S1A). We found that cells express-
ing CD14 and/or CD1c could be separated into four CD33+ clus-
ters (A, B, C, and D) (Figure 1A; Figure S1B). Contaminating clus-
ters containing B and T lymphocytes and neutrophils were
excluded from the analysis (Figure S1B). Hierarchical clustering
performed on averaged single cell expression data within clus-
ters showed that A and B were closer to each other than any
of the other subsets (Figures 1B–1D). Cluster D fell between
the group of clusters A and B and cluster C (Figure 1B). Classical
cDC2 markers, such as CLEC10A, FCER1A, and major histo-
compatibility complex (MHC) class II genes (HLA-DQA, HLA-
DPA,HLA-DRA, and theMHC class II-associated invariant chain
CD74) were expressed prominently in clusters A, B, and D (Fig-
ures 1D and 1E; Figure S1C; Heidkamp et al., 2016; Lavin et al.,
2017; Segura et al., 2013). In contrast, monocytic markers such
as CD14, S100A8, S100A9, S100A12, and VCAN were moreuman Peripheral Blood
/or CD1c. Cells expressing CD14 and/or CD1c were sorted by flow cytometry
resolution of CD1c+ subsets, the cellular input was enriched in CD1high cells
quenced. Dimensionality reduction of scRNA-seq data was performed using
lusters A, B, C, and D were identified using the shared nearest neighbor (SNN)
sion (14,933 genes).
arisons between groups A, B, and D.
ter.
of representative DEGs (226 total DEGs). Feature plots display the average
plot defined in (A).
ified by Villani et al. (2017) and Yin et al. (2017). (**p < 0.01, ****p < 0.0001, one-
ed clustering of flow cytometry data using the FlowSOM algorithm. tSNE and
c, FcεRI, CD14, CD163, BTLA, CD123, and CD5. tSNE plots (right) display the
he expression of specific markers in clusters 1, 2, and 3 when combined in 2-
cytes in circulating PBMCs and histograms showing expression of S100A8/9,
yte populations as defined in (H).
enes.
rs in scRNA-seq analysis (A, B, C, and D, left) and in bulk RNA-seq analysis on
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compared with D (Figures 1D and 1E). Finally, expression of
the C5 receptor C5AR1 (CD88) was found to be restricted to
cluster C together with SOD2 and RBP7 (Figures 1D and 1E).
To determine whether our clustering reflects previously
published data, we decided to evaluate the expression of gene
signatures obtained from Villani et al. (2017). We found that
signature genes discriminating cDC2 within CD14lo cells were
mostly represented in clusters A and B, confirming their
identity (Figure 1F). Likewise, signature genes defining DC3s
within CD14lo cells (Villani et al., 2017) and CD14+ monocytes
were significantly enriched in cluster D and cluster C, respec-
tively (Figure 1F). Of note, genes enriched in DC3s compared
with cDC2s (S100A8, S100A9, andCD14) were highly expressed
in clusters C and D (Figure 1E; Figure S1E).This underlines
the need to integrate a monocyte reference in any comparison
aiming to define DC3s. We conclude that scRNA-seq analysis
identifies DC3s (cluster D) as a specific subset sharing transcrip-
tional features of cDC2s (clusters A and B) and monocytes
(cluster C).
Next we sought to define a flow cytometry-based strategy
enabling analysis and prospective isolation of DC3s in blood.
To this end, we performed an unsupervised flow cytometry
data analysis based on genes identified by scRNA-seq (e.g.,
CD88, CD14, FcεRI, and CD1c) as well as markers previously
associated with cDC2s (e.g., BTLA and CD5) (Yin et al., 2017)
and DC3s (e.g., CD163) (Villani et al., 2017), even though they
were not detected in the scRNA-seq analysis.We identified three
main clusters (1, 2, and 3) together with a rarer cluster (4) of CD5hi
cells (Figure 1G; Figure S1D). Cluster 4 appeared to be CD123hi
contamination of AS-DCs (Figure S1D). Cluster 1 highly ex-
pressed CD88, aligning with monocyte cluster C identified by
scRNA-seq. Cluster 2 did not express the monocyte-associated
markers CD14 andCD88 but was characterized by expression of
CD1c, FcεRI, and B and T lymphocyte attenuator (BTLA) (Fig-
ure 1G). In addition, cluster 2 showed heterogeneous expression
of CD5 (Figure 1G). Similar to cluster 2, cluster 3 did not express
the monocytic marker CD88 and displayed higher amounts of
CD1c and FcεRI. However, cluster 3 could be distinguished
from cluster 2 by higher expression of CD163 and heteroge-
neous expression of CD14 (Figure 1G). The unsupervised flow
cytometry analysis allowed us to define a simple gating strategy
enabling prospective isolation of monocytes (CD88+CD14+),
cDC2s (CD5+ and CD5CD88CD1c+BTLA+CD163), and
DC3s (CD88CD1c+BTLACD163+) (Figure 1H).
To further validate the flow cytometry-based identification of
cell subsets, we performed bulk RNA-seq analysis of sorted
monocytes, cDC2s (CD5+ and CD5), DC3s, plasmacytoid
DCs (pDCs), and AS-DCs (Figure S1E). Principal-component
analysis (PCA) indicated that, overall, CD5+ and CD5 cDC2s,
DC3s, and monocytes separated from pDCs and AS-DCs along
the PC1 axis, accounting for 61% variance (Figure 1I). CD5+ and
CD5 cDC2 clustered closely together, and DC3s separated
clearly from cDC2s and monocytes (Figure 1I; Figure S1F). Hier-
archical clustering (HC) and differentially expressed gene anal-
ysis led to the same conclusion, with DC3s sitting between
monocytes and cDC2s (CD5+ andCD5) (Figure 1J; Figure S1G).
Overall, DC3s are closer to cDC2s than monocytes (Figures 1I
and 1J).4 Immunity 53, 1–18, August 18, 2020Together, this validates that cellular clusters isolated by a flow
cytometry-based approach align to clusters identified by unbi-
ased scRNA-seq (Figure 1K).
We conclude that DC3s are a separable entity within CD1c+
cells, defined by a distinct gene expression profile, and that
they can be prospectively isolated using CD88, CD1c, CD163,
and BTLA (Figure S1H). scRNA-seq and bulk gene expression
profiling identify markers shared between DC3s and cDC2s
(e.g., CLEC10A and FCER1A) and markers shared between
DC3s and monocytes (such as S100A8, S100A9, CD14,
and CD163).
DC3s Give Rise to CD14+CD1c+ DCs Infiltrating Tumors
Tumor-infiltrating CD14+CD1c+ DCs have been reported in mul-
tiple instances, including ovarian cancer ascites (Segura et al.,
2013), breast cancer (Michea et al., 2018), and melanoma (Bak-
dash et al., 2016; Binnewies et al., 2019). Therefore, we asked
whether CD14+CD1c+ cells would align with DC3s. To this
end, we analyzed mononuclear phagocytes infiltrating luminal
breast cancer primary tumors. Using the gating strategy
described in Figure 1, we found that, after exclusion of CD88+
monocytes and macrophages, the remaining CD45+HLA-DR+
CD123CD88 fraction contained cDC1s, CD14CD1c+
CD163CD5+ cDC2s (CD5+ cDC2s), and CD14+CD1c+CD163+
CD5 DC3s (CD14+ DC3s) (Figure 2A; Figure S2A). At this stage,
we observed that CD163 and BTLAwere particularly susceptible
to enzymatic digestion of solid tissue, preventing consistent and
reliable quantification of cells throughout the cohort of samples.
Hence, we adopted a more restrictive definition of cDC2s and
DC3s as CD1c+CD14CD5+ and CD1c+CD14+CD5 cells,
respectively (Figure 2A). This strategy enabled isolation of
CD5+ cDC2s and CD14+ DC3s in peripheral tissues even though
it might result in underestimation of their absolute numbers.
Nevertheless, both subsets aligned phenotypically with their
blood counterparts (Figures S2B and S2C) and expressed
markers reported previously for CD1c+CD14+ iDCs, such as
CD11c and FcεRI (Figure 2A; Segura et al., 2013).
DC3s were consistently identified in 25 samples of primary tu-
mors of clinical stages I, II, and III (Figure S2D). Macrophages
represented by far the most abundant population. DC3s out-
numbered cDC1s but were on par with bona fide CD5+ cDC2s
(Figure 2B). The relative abundance of DC3s did not correlate
with disease progression (Figure S2D) or with macrophages or
cDCs (Figure 2C). In contrast, cDC1 infiltration correlated with
cDC2s (Figure 2C).
Bulk RNA-seq analysis of CD1c+CD14+ cells sorted from tu-
mor-invaded lymph nodes indicated that they displayed a similar
expression profile as blood DC3s (high expression of cDC2
markers such as CLEC10A and FCER1A combined with low
expression of monocyte-associated markers such as C5AR1
and SOD2) (Figure 2D). Gene set enrichment analysis (GSEA)
revealed that CD14+CD1c+ were more enriched for the
DC3 > cDC2 signature compared with CD1c+ cells (normalized
enrichment score [NES], 2.06; p = 0.0; Subramanian et al.,
2005; Villani et al., 2017). In addition, CD14+CD1c+ were more
enriched for the DC3 > monocyte (Mono) signature compared
with CD14+ cells (NES, 1.42; p = 0.02; Villani et al., 2017; Fig-
ure 2E). Conversely, compared with CD1c+CD14+, the cDC2 >
DC3 and Mono > DC3 gene signatures were enriched in
Figure 2. DC3s Infiltrate Human Breast Tumors
(A) Representative gating strategy used to define macrophages, CD5+ cDC2s, and CD14+ DC3s and histograms showing the expression of CD163, FcεRI, BTLA,
and CD11c in human breast cancer primary tumors.
(B) Violin plot quantifying cDC1, CD5+cDC2, CD14+ DC3, and CD14+CD88+ macrophage subsets identified in (A) in human breast cancer primary tumors (n = 25;
*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, one-way ANOVA test).
(C) Pearson correlations of the frequencies of macrophages, cDC1s, CD5+cDC2s, and CD14+ DC3s within HLA-DR+ cells in human breast cancer primary tumors
(red, significantly correlated p < 0.05; black, not correlated).
(D) HC showing the relative expression of markers used for subset identification in Figure 1 in CD1c+, CD1c+CD14+, and CD14+ cells from invaded lymph nodes
draining human breast cancer primary tumors.
(E) GSEA of pairwise comparisons of CD1c+CD14+ cells with CD1c+ or CD14+ from invaded lymph nodes draining human breast cancer primary tumors. Gene
signatures of blood DC3s compared with cDC2s (DC3 > cDC2) or CD14+ monocytes (DC3 > Mono) and, vice versa, of blood cDC2s (cDC2 > DC3) or CD14+
monocytes (Mono > DC3) compared with DC3s were used (Villani et al., 2017).
See also Figure S2 and Table S2.
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cells, respectively (Figure 2E).
We conclude that CD11c+FcεRI +CD14+CD1c+ iDCs infil-
trating breast cancer align with DC3s.
Inflammatory cues promoting mobilization of CD14+CD1c+
cells at the site of inflammation are not fully defined. Mouse
studies define GM-CSF as a likely candidate (Mach et al.,
2000; Menezes et al., 2016). For this reason, we decided totest whether GM-CSF was sufficient to mobilize human CD14+
CD1c+ DCs in a humanized mouse metastatic lung model. We
generated B16mousemelanoma engineered to overexpress hu-
man GM-CSF (B16_huGM) or FLT3L (B16_huFLT3L) (Fig-
ure S3A). Immunodeficient NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ
(NSG) mice were injected intravenously with B16 control
(CTRL), B16_huGM, or B16_huFLT3L (Figure 3A). Lung metas-
tasis-bearing mice were engrafted with human peripheral bloodImmunity 53, 1–18, August 18, 2020 5
Figure 3. DC3s Give Rise to CD14+CD1c+ DCs at Inflammatory Sites
(A) Experimental model. NSGmice were injected intravenously (i.v.) with B16_CTRL, B16_huFLT3L, or B16_huGM on day 0. On days 7 and 8, 108 human PBMCs
were injected i.v. Metastatic lungs were collected on day 9.
(B) Pseudocolor images of B16_huGM (green) metastatic lung on day 9 post-injection, stained for human CD45 (red). Nuclei were stained with Hoechst (blue).
Scale bar, 100 mm.
(C) Gating strategy for cDC2 and DC3 identification in B16_huGM and B16_huFLT3L metastatic mouse lung and histograms showing the expression of CD163,
CD206, and Clec10A. The bar graph summarizes the frequency of cDC2s and DC3s among total HLA-DR+ cells in metastatic B16_CTRL, B16_huFLT3L, or
B16_huGM mouse lungs (n = 3 independent mice; **p < 0.01, ***p < 0.001, ****p < 0.0001, one-way ANOVA test).
(D) Flow cytometry analysis of flow cytometry-sorted cDC2s, DC3s, and CD14+ monocytes after 2 days of culture with MS5 stromal cells expressing human GM-
CSF (MS5_GM). Bar graphs show the frequency of output cells among total huCD45+ cells (n = 4–5 healthy donors).
(E) Histograms showing CD14 expression on cDC2s, DC3s, and CD14+ monocytes before and after 2 days of coculture with MS5_GM and bar graphs sum-
marizing the frequency of CD14 expression within each cell type (n = 5 healthy donors, **p < 0.01, Mann-Whitney two-tailed t test).
See also Figures S3 and S4 and Table S1.
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kocytes were found in lung tumor foci and juxta-tumor areas
(Figure 3B; Figures S3B and S3C). Flow cytometry analysis of
metastatic lungs showed that FLT3L, but not GM-CSF, pro-
motes expansion of CD1c+CD5+ cells aligning with blood
cDC2s (Figure 3C, blue). In contrast, GM-CSF, but not FLT3L,
led to accumulation of CD1c+CD14+ cells aligning with blood
DC3s (Figure 3C, orange; Figure S3D, orange). As shown for
circulating peripheral blood subsets in Figure 1, FLT3L-
dependent cDC2s and GM-CSF-dependent DC3s shared
expression of Clec10A, CD11c, and FcεRI (Figure 3C; Fig-
ure S3E). All tumor-bearing lungs contained some monocytes
and/or macrophages (CD14+CD88+) (Figure 3C; Figure S3B).
To further establish alignment of GM-CSF-mobilized DC3s,
we performed an unbiased scRNA-seq on human CD45+-
HLA-DR+ cells expressing CD14 and/or CD1c (Figures S3F
and S3G). Two major clusters could be identified. Cluster
0 was characterized by expression of genes associated with
DC3s and cDC2s, such as CLEC10A, FCER1A, and CD74
(Figures S3H and S3I), and was enriched in DC3 differentially
expressed transcripts (Villani et al., 2017; Figure S3J).
Conversely, cluster 1 expressed markers defining monocytes
(SOD2, C5AR1, and G0S2) and CXCL2, CXCL3, and CXCL8
chemokines (Figures S3H and S3I). We conclude that GM-
CSF drives mobilization of CD14+CD1c+ cells aligning pheno-
typically with circulating DC3s.
We next wondered whether GM-CSF could induce trans-
differentiation of circulating cDC2s or monocytes into CD14+
CD1c+ DC3s. To test this hypothesis, cDC2s, DC3s, and
monocytes were sorted by flow cytometry from blood and co-
cultured in vitro in the presence of GM-CSF-expressing stro-
mal cells (MS5_GM). After 2 days, cDC2s did not acquire
CD163 or CD14 expression (Figure 3D). In contrast, DC3s
did upregulate CD14 (Figures 3D and 3E). We found that
monocytes differentiated into CD16+ and CD16 macro-
phages (Figure 3D). Importantly, CD88+CD1cCD14+ mono-
cytes did not give rise to CD1chiCD163hi DC3s (Figure 3D).Figure 4. DC3s Differentiate from Hematopoietic Progenitors upon
(cMoPs) or cDC-Committed Progenitors (CDPs)
(A) Flow cytometry analysis of cord blood-derived CD34+ HSPCs cultured on st
without human recombinant GM-CSF (MS5_FS12+recGM-CSF) for 14 days.
(B) Flow cytometry plots of BTLA and CD163 expression within CD1c+CD14
numbers of differentiated CD1c+CD14 cDC2s and CD1c+CD14+ DC3s (a line r
coxon test).
(C) Bar graphs summarizing the absolute numbers of CD1c+CD14CD163 cD
CD34+ HSPCs cocultured for 14 days with stromal cells expressing human FLT3
median; n = 5–7 independent cord blood donors, *p < 0.05, **p < 0.01, ***p < 0.0
(D) HC based on 19,791 protein-coding genes of in-vitro-generated subsets dif
human recombinant GM-CSF (MS5_FS12+recGM-CSF). Each dot represents an
(E) Volcano plots showing the DEGs between in-vitro-generated DC3s cells (oran
and brown, right plot). Genes with Log2(fold change, FC) > ±2 and a false discov
(F) GSEA of pairwise comparisons of DC3s with cDC2s or macrophages generate
compared with cDC2s (DC3 > cDC2) or blood DC3s compared with CD14+ mon
enrichment score).
(G) BubbleMap summarizing the enrichment of defined gene sets in pairwise
macrophages. Gene signatures (gene sets) of blood DC3s compared with cDC2
cDC2s (cDC2 > DC3) or CD14+ monocytes (Mono > DC3) compared with DC3s
(H) Flow cytometry analysis of cord blood-derived CDPs, cMoPs, and GMDPs
absolute number of differentiated cells from each progenitor (a line represents th
See also Figure S5 and Table S1.
8 Immunity 53, 1–18, August 18, 2020Addition of IL-4 to GM-CSF culture did not affect the outcome
(Figure S4A). The lack of trans-differentiation of cDC2s or
monocytes into DC3s was also confirmed in vivo upon adop-
tive transfer into immunodeficient NSG mice carrying GM-
CSF-expressing tumors (Figures S4B and S4C). Overall, we
conclude that CD88CD14+CD1c+ cells can differentiate
from DC3s independent of cDC or monocytic lineages.
GM-CSF Stimulates Differentiation of CD34+
Hematopoietic Progenitors into DC3s In Vitro
We next wondered how DC3s would differentiate from bone
marrow progenitors. To this end, we sought to define a culture
system capable of generating DC3s together with cDC2s and
macrophages. We cocultured human cord blood-derived
CD34+ hematopoietic stem and progenitor cells (HSPCs) with
stromal cells engineered to overexpress cDC-promoting factors
(membrane-bound FLT3L together with stem cell factor (SCF)
and CXCL12 [MS5_FS12]; Anselmi et al., 2020) in the presence
or absence of GM-CSF (Figure 4A; Figure S5A). We found that
GM-CSF increased differentiation of CD1c+CD14+CD163+ cells
(orange) phenotypically aligning with blood DC3s (Figures 4A
and 4B). CD1c+CD14 cells did not express CD163, suggesting
that theymostly align with cDC2s. In addition, CD163 expression
was restricted to CD1c+CD14+ cells (Figure 4B). GM-CSF alone
(MS5_GM), but not FLT3L, was sufficient to induce differentia-
tion of DC3s in vitro (Figure 4C). In contrast, FLT3L (MS5_FL)
was sufficient to induce differentiation of cDC2s (Figure 4C).
We conclude that cDC2s and DC3s have distinct growth factor
requirements.
We next intended to determine whether the transcriptional
landscape of in-vitro-generated DC3s from stromal cell cocul-
tures aligned with their in vivo counterparts. Bulk RNA-seq anal-
ysis of in-vitro-generated cells showed that CD14+CD1c+ DC3s
(orange) sat between cDC2s (blue and turquoise) and macro-
phages (gray and brown) (Figure 4D). Of note, CD1c+CD14 cells
generated in vitro were heterogenous for CD206 expression
and were therefore analyzed as two independent subsetsGM-CSF Exposure Independent of Mono-Committed Progenitors
romal cells expressing human FLT3L, SCF, and CXCL12 (MS5_FS12) with or
and CD1c+CD14+ cells identified in (A). Bar graphs summarize the absolute
epresents the median; n = 6 independent cord blood donors, *p < 0.05, Wil-
C2s and CD1c+CD14+CD163+ DC3s differentiated from cord blood-derived
L (MS5_FL), GM-CSF (MS5_GM), or neither (MS5_CTRL) (a line represents the
01, Wilcoxon test).
ferentiated from CD34+ HSPCs cultured with MS5_FS12 supplemented with
average of three donors.
ge) compared with cDC2s (blue and turquoise, left plot) or macrophages (gray
ery rate (FDR)-adjusted p value of less than 0.05 were considered significant.
d in vitro. Gene signatures (gene set) defining genes upregulated in blood DC3s
ocytes (DC3 > CD14 Mono) were used (Villani et al., 2017) (NES, normalized
comparisons of in-vitro-differentiated DC3s versus in vitro cDC2s or in vitro
s (DC3 > cDC2) or CD14+ monocytes (DC3 > Mono) and, vice versa, of blood
were used (Villani et al., 2017).
cultured for 7 days with MS5_FS12 or MS5_GM. Bar graphs summarize the
e median, n = 4–7 independent cord blood donors).
Figure 5. Single-Cell Analysis of DC3 Commitment
(A) Flow cytometry analysis of bulk (500 cells) or single CD34+CD38+CD123CD64 progenitor cells cocultured for 14 days with MS5_FS12 supplemented with
recombinant human GM-CSF (MS5_FS12+recGM-CSF). Flow cytometry plots resulting from single CD34+CD38+CD123CD64 progenitor cells with different
potentials are shown as representative examples (n = 355 cells from 2 independent experiments).
(B) HC of lineage potential from single CD34+CD38+CD123CD64 progenitor cells (n = 355).
(C) Bar graph and Venn diagram summarizing the frequency of the potential of mono-, bi-, tri-, or multipotent individual CD34+CD38+CD123CD64 cells within
the total wells analyzed (n = 355).
(D) Bar graphs summarizing the frequency ofmono-, bi-, tri-, or multipotent individual CD34+CD38+CD123CD64 cells among DC3-generating progenitors only.
An orange bar represents the frequency of DC3-restricted progenitors.
(E) Cell surface phenotype of DC3-restricted progenitors before differentiation cultures inferred by index flow cytometry sorting. tSNE plots display an overlay of
total CD45+ cells (gray) and DC3-restricted progenitor cells (orange) (top left). Shown is relative expression of themarkers CD45RA, CD38, CD34, CD10, Clec12A,
CD64, CD123, CD163, and SIRPa.
(legend continued on next page)
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ure S5B). However, both subsets displayed very similar
transcriptomes regardless of CD206 expression, and the CD1c+
CD14CD206+ and CD1c+CD14CD206 fractions strongly
resembled circulating cDC2s (Anselmi et al., 2020).
Further analysis of differentially expressed genes (DEGs)
showed that in vitroDC3s differed from in vitro cDC2s by expres-
sion of monocyte-associated markers such as S100A8, S100A9,
S100A12, and CD14 (Figure 4E; Figure S5C). Conversely, in vitro
cDC2s displayed higher expression of CD1C, LAMP3, CD52,
and LTB, as reported for lung cDC2s (Lavin et al., 2017; Fig-
ure 4E; Figure S5C). Using the GSEA methodology (Subrama-
nian et al., 2005), we found that the set of genes upregulated in
primary DC3s compared with cDC2s (DC3 > cDC2 from Villani
et al., 2017) was enriched in GM-CSF-dependent in vitro DC3s
compared with in vitro cDC2s (Figure 4F). Of note, GM-CSF-
exposed cDC2s did not convert to DC3s (Figures S5D and
S5E). We found that markers common for primary cDC2s and
DC3s (CLEC10A, Figure 1) were higher in in vitro DC3s
compared with in vitro macrophages (Figure 4E; Heidkamp
et al., 2016). Conversely, in vitro macrophages expressed more
FCGR1A, C5AR1 (CD88), CXCL8, CXCL1, CXCL2, CXCL3,
CCL2, CCL3, and CCL7 compared with in vitro DC3s (Ruffell
et al., 2009; Figure 4E; Figures S5C and S5F). Genes upregulated
in primary DC3s compared with CD14+ monocytes (DC3 >
CD14+ Mono from Villani et al., 2017) were significantly enriched
in in vitro DC3s compared with macrophages (Figures 4F and
4G).We conclude that GM-CSF drives, in vitro, the differentiation
of DC3s aligning to primary blood DC3s.
DC3s Develop via a Differentiation Pathway
Independent of CDPs and cMoPs
The developmental relationship between DC3s and cDCs or
monocyte lineages is not known. A classical view defines the
development of phagocytes as a stepwise and ordered loss of
developmental potential concomitant with lineage commitment.
Historically, this process has been identified using prospective
isolation of progenitor populations of decreasing potential. Spe-
cifically, early granulocyte-monocyte and DC progenitors
(GMDPs) carries a tri-lineage potential (Lee et al., 2015b). Loss
of neutrophil potential defines monocyte and DC progenitors
(MDPs) (Lee et al., 2015b). Loss of monocyte potential defines
CDPs, which generate cDCs via a pre-cDC intermediate (Breton
et al., 2015, 2016; Lee et al., 2015b; Naik et al., 2007; Onai et al.,
2007; See et al., 2017). Finally, loss of DC and neutrophil poten-
tial defines monocyte-committed progenitors (cMoPs) (Kawa-
mura et al., 2017). Having established the growth factor require-
ments for DC3 development, we decided to test the contribution
of CDPs and cMoPs to generation of DC3s. Flow cytometry-
sorted CDPs and cMoPs and the remaining GMDP-containing
fraction (CD34+CD38+CD45RA+CD123CD64) isolated from
cord blood-derived HSPCs (see the gating strategy in Fig-
ure S5G) were cocultured with stromal cells supporting cDC
(MS5_FS12) or DC3 (MS5_GM) differentiation.(F) Validation experiment for identification of Clec12A as a marker for DC3
CD34+CD38+CD45RA+CD123CD64Clec12A and Clec12A+ cells. 500 cells we
of differentiated DC3s from each bulk population (n = 4 healthy donors, *p < 0.05
See also Figure S5.
10 Immunity 53, 1–18, August 18, 2020Flow cytometry analysis after 7 days of culture showed that
CDP gave rise exclusively to cDC1s and cDC2s in MS5_FS12
cocultures, as described previously (Figure 4H; Figure S5H;
Lee et al., 2015b). cMoP cultures gave rise solely to CD14+
CD1c cells, as described previously (Figure 4H; Figure S5H;
Kawamura et al., 2017). As expected, the GMDP-containing
fraction gave rise to granulocytes, macrophages, and cDC2s.
Importantly, the GMDP-containing fraction also gave rise to
DC3s in MS5_GM coculture (Figure 4H; Figure S5H). Therefore,
we asked whether DC3s would arise directly from a multipotent
progenitor or via formation of an intermediate DC3-committed
progenitor devoid of any other lineage potential.
To address this question in unbiased settings, we devel-
oped a single cell culture of CD34+CD38+CD123CD64 pro-
genitors distinct from CDPs or cMoPs (Figure 5A). We chose
to combine MS5_FS12 with soluble GM-CSF for two reasons:
(1) GM-CSF alone did not support growth of individual pro-
genitors (Figure S5I), and (2) MS5_FS12 coculture was found
to more efficiently support cDC and monocyte differentiation
(Figure 4G).
Flow cytometry analysis of 14-day progeny of individual
progenitor cultures revealed multiple patterns of develop-
mental potential (Figure 5A). Overall, the granulocyte potential
was segregated from the potential for mononuclear phago-
cytes (Figure 5B). We found that only 0.3% of progenitors
could differentiate into all four lineages corresponding to the
GMDP functional definition (Figure 5D). Most individual pro-
genitors gave rise to single lineage progeny (Figures 5C and
5D). Unipotent wells containing only neutrophils represented
the most abundant outcome (39.4%), followed by macro-
phage-only (26.8%) and cDC-only (5.63%) wells (Figure 5C).
Most individual progenitors endowed with DC3 potential had
multi-lineage potential. DC3 potential was more associated
with mononuclear phagocytes rather than granulocyte poten-
tial (61.4% and 19.3% of DC3-containing wells, respectively)
(Figure 5D). Importantly, we also identified a minor fraction
of individual progenitors giving rise exclusively to DC3s (Fig-
ures 5B–5D).
We next aimed to further define the cell surface phenotype
of progenitors endowed with DC3 potential. To this end, we
attempted to establish correlations between the cell surface
phenotype of single sorted cells (inferred from index flow
cytometry sorting) and their developmental potential. A poste-
riori identification of the cell surface phenotype of DC3-
committed progenitors revealed that they had a CD34+CD38+
CD45RAintCD123CD64SIRPaloCD10Clec12A+ phenotype
(Figure 5E). As validation, we showed that the potential for
DC3s lay in the Clec12A+ population of the GMDP-containing
fraction (Figure 5F). We conclude that DC3s can develop via a
DC3-restricted intermediate distinct from cDC-restricted
CDPs or monocyte-restricted cMoPs. Even though the exis-
tence of a DC3-commited unipotent progenitor is not formally
proven, our data are compatible with the notion that DC3
specification arises downstream of MDP.-committed progenitors. Shown is flow cytometry analysis of bulk-sorted
re cocultured with MS5_GM for 7 days. The bar graph summarizes the number
, Mann-Whitney two-tailed t test).
Figure 6. DC3s Respond to TLR Stimulation
We performed bulk RNA-seq analysis of BTLA+CD5+ and BTLA+CD5 cDC2s, DC3s, and monocytes sorted as shown in Figure 1H and stimulated overnight (16
h, 3 donors) or not (4 donors) with a TLR agonist cocktail (25 mg/mL poly(I:C), 1 mg/mL R848, and 10 ng/mL LPS). For activation of cDC2s, BTLA+CD5+ and
BTLA+CD5 were pooled.
(A) PCA analysis for all genes.
(B) Venn diagram summarizing the number of activation-induced DEGs upregulated in stimulated compared with unstimulated cells within each cell population.
(C) Volcano plots showing DEGs between TLR agonist-stimulated DC3s compared with TLR agonist-stimulated cDC2s or TLR agonist-stimulated monocytes.
Genes with Log2(FC) > ±2 and a FDR-adjusted p value of less than 0.05 were considered significant.
(legend continued on next page)
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Differentiation of CD103+ T Cells
We next aimed to understand the immunological function of
DC3s and to compare it with cDC2s and monocytes. First, we
decided to test the responsiveness of DC3s, cDC2s, and mono-
cytes to a cocktail of Toll-like receptor (TLR) agonists. cDC2s,
DC3s, andmonocytes were sorted by flow cytometry from blood
and stimulated overnight ex vivo. PCA analysis of the total tran-
scriptome of unstimulated and stimulated populations evidenced
that all subsets underwent a certain degree of convergence in
their transcriptome (Figure 6A). In support of this, we found an
important overlap in the set of activation-induced genes defined
for each subset (1,344 genes; Figure 6B). Despite the relative
convergence of activated cells, we found that overnight activa-
tion did not compromise cell surface discrimination of DC3s
from cDC2s and monocytes (Figure S6A). Indeed, TLR-activated
DC3s could still be discriminated from TLR-activated cDC2s by
437 DEGs or from TLR-activated monocytes by 1,293 genes
(Figure 6C). The same was true for the pairwise comparison of
activated cDC2s and circulating DC3s (Figure S6B). In sum, we
conclude that innate activation does not trigger conversion of
cDC2s or monocytes into DC3s despite induction of a common
transcriptional response to TLR stimulation.
From the perspective of adaptive immunity, activated DC3s
shared a lot of common features with activated cDC2s but less
with activated monocytes: (1) stimulated DC3s and cDC2s upre-
gulated CCR7 upon activation (Figure 6D), potentially enabling
their ability to migrate toward T cell zones; (2) activated DC3s
and cDC2s upregulated cell surface co-stimulatory molecules
(CD80, CD86, CD70, and CD40; Figure 6E and 6F); (3) activated
DC3s and cDC2s efficiently increased the expression of T cell-
attracting chemokines such as CCL5 (Figures 6G and 6H),
CCL19, CCL17, CCL22, CXCL9, CXCL10, CXCL11, and
CXCL13 (Figure S6C); and (4) activated DC3s and cDC2s pro-
duced higher amounts of IL-12p70, IL-23, IL27, and IL-10 (Fig-
ures 6G and 6H; Figure S6E).
In addition, activated DC3s shared some common features
with activated monocytes that are less pronounced in activated
cDC2s: (i) activated DC3s and monocytes secreted more inflam-
matory cytokines, such as tumor necrosis factor alpha (TNF-a)
and IL-1b (Figures 6G and 6H); and (2) activated DC3s and acti-
vated monocytes upregulated inflammatory chemokines, such
as CCL2 (Figures 6G and 6H), CCL1, and CCL3 (Figure S6C) or
granulocytes attracting CXCL1, CXCL3, and CXCL5 (Figures
S6C and S6D).
Collectively, our data suggest that the transcriptome and se-
cretome of activated DC3s, unlike the ones of activated mono-
cytes, are consistent with a function in priming of naive T cells.(D) Bar graph summarizing relative CCR7 gene expression within TLR-agonist st
represents the median; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, one-w
(E) Histograms showing the frequency and median of fluorescence intensity (MFI
populations.
(F) Heatmap showing the relative gene expression of selected costimulatory m
populations.
(G) Quantification of cytokines and chemokines secreted by cDC2s, DC3s, and
agonists (n = 9 healthy donors; a line represents the median; *p < 0.05, **p < 0,0
(H) Heatmap showing the relative gene expression of cytokines and chemokine
phagocyte populations.
See also Figure S6 and Table S1.
12 Immunity 53, 1–18, August 18, 2020To directly test the T cell priming capabilities of DC3s, we per-
formed 5-day cocultures of flow cytometry-sorted, activated
DC3s, cDC2s, and monocytes (see the cell sorting strategy in
Figure S7A) with allogenic CD45RA+ naive T cells in the presence
of a synthetic superantigen. We found that activated DC3s and
cDC2s, unlike monocytes, triggered proliferative expansion
and effector differentiation in CD4+ and CD8+ T cells probed
by CD45RO acquisition (Figure S7B). The same results were
also obtained using in-vitro-generated DC3s (Figure S7C). In
contrast to monocytes, activated DC3s and cDC2s induced
interferon g (IFN-g)- and TNF-a-producing CD4+ and CD8+
T cells but not IL- 17A (Figure 7A; Figure S7D). We found that
DC3s had a specific ability to efficiently trigger CD103 expres-
sion in CD8+ T cells (Figure 7B), even without the presence of
superantigen (Figure S7E). CD103 expression is a hallmark of tis-
sue-resident memory T (TRM) cells because of its interaction with
E-cadherin (Mueller and Mackay, 2016). Mechanistically, multi-
ple factors, including transforming growth factor b (TGF-b),
have been proposed to induce CD103 expression on T cells (Mu-
eller and Mackay, 2016; Rihs et al., 1996; Yu et al., 2013). Here
we showed that anti-TGF-b neutralizing antibodies, but not
others, blocked the expression of CD103 on CD8+ T cells (Fig-
ure 7C; Figure S7F).
We next wondered whether CD103+ T cells aligned with bona
fide TRM cells isolated from human tissue. To this end, we eval-
uated the gene expression profile of CD103 and CD103+
CD8+ T cells obtained after coculture of naive T cells with acti-
vated DC3s (Figure S7G). Using the GSEA methodology (Subra-
manian et al., 2005), we found that the signatures obtained for
breast cancer or lung tissue CD103+ TRM cells (Hombrink et al.,
2016; Kumar et al., 2017; Savas et al., 2018) were enriched in
CD103+ T cells compared with CD103 T cells induced by
DC3s (Figure 7D). DEG analysis revealed that human TRM cell
markers such as NUSAP1, DUSP4, CXCR6, and FASLG
(Figure 7E; Hombrink et al., 2016; Kumar et al., 2017; Savas
et al., 2018) were upregulated in CD103+ compared with
CD103 CD8+ T cells. In addition, DC3-activated CD103+
CD8+ T cells expressed core components of the cytotoxic
machinery (PRF1 and GZMA), as reported earlier for breast can-
cer-invading TRM cells (Figure 7E; Savas et al., 2018).
CD8+CD103+ TRM cell infiltration has a protective prognosis
value in breast cancer (Savas et al., 2018; Wang et al., 2016).
To test the physiological relevance of DC3-dependent induction
of CD8+CD103+ T cells, we analyzed CD103 and CD69 expres-
sion in CD3+CD8+ T cells from 18 samples of primary luminal
breast cancer (Figure 7F). We found that CD8+CD103+CD69+
T cells were present across different cancer stages (Figure 7G).
The frequency of CD8+CD103+CD69+ T cells was positivelyimulated or unstimulated mononuclear phagocyte populations (n = 3–4; a line
ay ANOVA test).
) of CD86 on TLR agonist-stimulated or unstimulated mononuclear phagocyte
olecules on TLR agonist-stimulated or unstimulated mononuclear phagocyte
CD14+ monocytes in response to overnight stimulation with a cocktail of TLR
1, ****p < 0,0001, one-way ANOVA test).
s analyzed in (G) within TLR-agonist stimulated or unstimulated mononuclear
Figure 7. DC3s Prime Naive T Cells and Drive Acquisition of the CD103+ TRM Phenotype
(A and B) Representative flow cytometry plots and quantification of CD4+ and CD8+ naive T cells cultured for 5 days with flow cytometry-sorted blood cDC2s,
DC3s, or CD14+ monocytes after overnight activation with TLR agonists (25 mg/mL poly(I:C), 1 mg/mL R848, and 10 ng/mL LPS) in the presence of a synthetic
(legend continued on next page)
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phagocytes (Figure 7H). Despite the statistical significance of
this correlation, it is important to underline that this was mainly
driven by a subset of the samples. This suggests that further
stratification of patients could help improve our understanding
of the relationship between TRM cells and DC3s in breast cancer.
Together, our results anchor DC3 function within the DC
lineage; DC3s, just like cDC2s but unlikemonocytes, are compe-
tent for priming and polarization of CD45RA+ naive T cells. In
addition, we define induction of bona fide TRM cell-like
CD103+CD8+ T cells (Yu et al., 2013) as a specific privilege of
DC3s but not cDC2s.
DISCUSSION
Using scRNA-seq and high-dimensional flow cytometry, we
provided evidence that DC3s represent a DC subset that can
be separated and isolated from other DC subtypes. Regarding
gene expression, our results are largely congruent with findings
reported in previous studies (Dutertre et al., 2019; Villani et al.,
2017). In addition, we provide a robust flow cytometry strategy
to identify and purify DC3s by taking in account CD14+ mono-
cytes and cDC2s. In agreement with previous studies, our re-
sults challenge the widely accepted notion that CD14 is a spe-
cific marker for monocytes (Dutertre et al., 2019; Villani et al.,
2017). Indeed, we clearly demonstrate that a large fraction of
DC3s expresses cell surface CD14. We identified CD88 (en-
coded by the C5AR1 gene) as a proper monocyte marker,
enabling prospective purification of monocytes devoid of
CD14+CD1c+ DC3s. We found that ex vivo GM-CSF cultures
of pure CD88+CD14+ monocytes did not give rise to
CD88-CD14+CD1c+ iDCs. Therefore, our findings provide an
incentive to carefully revisit the prevailing notion that CD14+
CD1c+ iDCs arise exclusively from monocytes in vivo.
From the DC perspective, we refined the strategy to analyze
the functional heterogeneity of CD1c+ DCs, including cDC2s
and DC3s. Indeed, previous studies have reported heteroge-
neous expression of CD5 in CD1c+ DCs (Dutertre et al., 2019;
Yin et al., 2017). However, our findings highlight that CD5CD1c+
DCs contain CD163 cDC2s and CD163+ DC3s, which are tran-
scriptionally distinct. Overall, our scRNA-seq and bulk RNA-seq
analyses cluster together CD5+ and CD5 cDC2s. However, thesuperantigen (Cytostim). Absolute numbers and frequencies of cytokine-producin
donors in 5 independent experiments; a line represents the median; *p < 0.05, **
(C) Representative flow cytometry plots and quantification showing CD103 expres
activated cell sorting (FACS) in the presence of 10 mg/mL of neutralizing antibod
dependent experiments; a line represents the median; *p < 0.05, **p < 0.01, ***p
(D and E) Bulk RNA-seq analysis of CD8+CD103 T cells (n = 3) and CD8+CD103
blood CD8+ T cells with blood DC3s activated overnight by TLR agonists.
(D) GSEA of pairwise comparisons of CD8+CD103+ T cells with CD8+CD103 T
CD103+CD69+CD8+ TRM cells were used (Hombrink et al., 2016; Kumar et al., 20
(E) Heatmap displaying 56 representative genes significantly upregulated in CD8+
205 DEGs). Selected genes are shared with at least one of the previously reported
2017; Savas et al., 2018).
(F–H) Correlative analysis of TRM cell content in luminal breast cancer primary tu
(F) Representative flow cytometry plots showing the gating strategy for CD103+C
(G) Quantification of CD103+CD69+CD8+ T cells in different stages of human bre
(H) Pearson correlation of the frequencies of the macrophages and cDC1, CD1c
T cells in human breast cancer primary tumors (red, significantly correlated p < 0
See also Figure S7 and Tables S1 and S2.
14 Immunity 53, 1–18, August 18, 2020developmental relationship between CD5 cDC2s, CD5+
cDC2s, and AS-DCs remains to be clarified (Dutertre et al.,
2019; See et al., 2017; Villani et al., 2017).
Because of CD1c expression and their relative similarity to
cDC2s, DC3s have been embedded in the group of cDCs.
Here we have provided substantial evidence arguing against
this notion. Indeed, a conservative definition of cDCs includes
(1) dependence on the FLT3L growth factor (Breton et al.,
2015; Guermonprez et al., 2013, 2019; McKenna et al., 2000;
Pulendran et al., 1998; Waskow et al., 2008) and (2) reliance
on the CDP and pre-cDC developmental pathway (Breton
et al., 2015, 2016; Guermonprez et al., 2019; Lee et al.,
2015b; Naik et al., 2007; Onai et al., 2007). Here we have
shown that DC3s do not meet any of these criteria. First,
FLT3L alone was poorly active in stimulating the production
of DC3s from CD34+ HSPCs in a controlled setting in vitro.
Conversely, GM-CSF drives the commitment of DC3s under
the same conditions. Moreover, we have shown that CDP did
not give rise to DC3s although they are competent to generate
cDC1s and cDC2s (Lee et al., 2015b). Taking in account the
heterogeneity of defined progenitor populations (Paul et al.,
2015), we developed single-cell cultures enabling analysis of
multiple lineage populations. Our single-cell cultures demon-
strated that DC3s develop from CLEC12A+ DC3-restricted pro-
genitors. In addition, the most frequent progenies differentiating
along with DC3s from a bi-potent progenitor were cDCs and
macrophages. This strongly suggest that DC3 progenitors
diverge downstream of the MDP stage (Fogg et al., 2006; Lee
et al., 2015a). Further studies will define more precisely the
cell surface and molecular phenotype of the DC3-restricted
progenitor. In support of a distinct regulation of cDC2s and
DC3s, we have shown that cDC2 infiltration in breast cancer
is correlated with cDC1s but not DC3s. Also, Dutertre et al.
(2019) have shown recently that DC3s, but not cDC2s, expand
in the blood of systemic lupus erythematosus patients (Dutertre
et al., 2019). Further delineation of the inflammatory cues and
transcription factors underpinning the development of the
DC3 lineage is needed.
Identification of DC3 as a cellular entity arising from a specific
lineage brings forward the question of their specific immune
function. We have shown that activated DC3s, just as cDC2s
but unlike monocytes, secrete high amounts of T cell-polarizingg and other activated T cells (A) and CD103+ T cells (B) are shown (n = 5 healthy
p < 0.01, ***p < 0.001, ****p < 0.0001, one-way ANOVA test).
sion on CD8+ naive T cells cocultured with blood DC3s sorted by fluorescence-
ies against TNF-a or TGF-b or an isotype CTRL (n = 4 healthy donors in 3 in-
< 0.001, ****p < 0.0001, one-way paired ANOVA test).
+ T cells (n = 3) sorted by flow cytometry after 5 days in vitro coculture of naive
cells. Gene signatures (gene set) defining genes upregulated in breast or lung
17; Savas et al., 2018).
CD103+ cells compared with CD8+CD103 induced by blood DC3s in vitro (of
gene signatures defining human TRM cells (Hombrink et al., 2016; Kumar et al.,
mors.
D69+CD8+ T cells in 21 human luminal breast cancer primary tumors.
ast tumors (stage I, n = 3; stage II, n = 13; stage III, n = 5).
+ CD14, and CD1c+ CD14 cells and the frequencies of CD103+CD69+CD8+
.05; black, not correlated).
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(CXCL9, CXCL10, CXCL11, and CCL5). In addition, DC3s also
secrete other cytokines (IL-10, IL-6, and TNF-a), some of which
were poorly secreted by cDC2s (e.g., TNF-a). DC3s are polyva-
lent phagocytes with a cytokine pattern encompassing T cell and
inflammation cues.
A quintessential defining feature of DCs is their capacity to
activate naive T cells. For instance, infiltration of CD1c+ DCs
is associated with priming of T cell effectors when regulatory
T (Treg) cell infiltration is low or Treg cell-mediated suppression
is alleviated by checkpoint blockade (Binnewies et al., 2019).
However, even when the heterogeneity of CD1c+ cells is appre-
ciated, including recruitment of CD14+CD1c+ DCs in tumor-
draining lymph nodes (Binnewies et al., 2019), little is known
about the function of CD1c+ subtypes. Therefore, we asked
whether the functions attributed to CD1c+ DCs would be carried
out by cDC2s and/or DC3s. We found that DC3s, like cDC2s but
unlike monocytes, primed and drove robust activation of naive
T cells into IFN-g- and TNF-a-secreting polyfunctional effectors
(Acosta-Rodriguez et al., 2007; Leal Rojas et al., 2017; Napolitani
et al., 2005; Nizzoli et al., 2013; Schlitzer et al., 2013; Yin
et al., 2017).
aE integrin (CD103) is a key marker of TRM cells through its
interaction with E-cadherin, participating in retention of T cells
at epithelial and mucosal sites (Mueller and Mackay, 2016).
Yu et al. (2013) have identified a feature of total CD1c+ DCs
in their ability to drive acquisition of CD103 in CD8+ T cells.
Here we have shown that DC3s, but not cDC2s, induced
expression of CD103 on CD8+ and CD4+ T cells. In addition,
we have shown that CD103+ T cells primed by DC3s ex vivo
align with bona fide TRM cells isolated from lung or breast
cancer (Hombrink et al., 2016; Kumar et al., 2017; Savas
et al., 2018). This finding is consistent with the existence of
early imprinting of the TRM cell program at the level of T cell
priming by DC3s. This notion is supported by a recent in vivo
study in a mouse model, evidencing early imprinting of the
TRM cell program during T cell priming in the lymph nodes
by aV integrin-expressing migratory DCs (Mani et al., 2019).
Further supporting this view, we found that (1) DC3s upregu-
lated CCR7 when activated by TLR agonists, potentially
acting as migratory DCs, and (2) blocking studies indicated
that TGF-b was required to prime CD103+ T cells. This role
of priming in lymph nodes does not exclude that tumor-infil-
trating DC3s might also provide TGF-b and other signals
important for maintenance of TRM cells, as demonstrated in
a mouse model (Mani et al., 2019). In support of this view,
we found that infiltration of DC3s was selectively associated
with the abundance of CD8+CD103+ T cells in luminal breast
cancer primary tumors. Further studies are needed to delin-
eate the full molecular mechanisms of CD103 induction
in T cells by DC3s and their physiological in vivo relevance
during immune responses. Indeed, CD103+CD8+ T cells are
a protective biomarker in triple-negative breast cancer
(Savas et al., 2018; Wang et al., 2016), and lung
CD103+CD8+ T cells are a hallmark of protective immunity af-
forded by influenza vaccination (Yu et al., 2013). This under-
lines the potential of DC3s to regulate tissue immunity and
defines them as targets for vaccines and immunotherapeutic
interventions.LIMITATIONS OF STUDY
We identify DC3s as CD88-CD1c+CD163+CD14+/-. Further
studies will be needed to determine if this phenotype corre-
sponds to all CD1c+CD14+ cells that had been reported in
various inflammatory settings.
We showed that DC3 differentiation is driven by GM-CSF in
humanized mouse metastatic lung model. However, human
circulating PBMCs were used in these experiments, preventing
the assessment of GM-CSF impact on bone marrow DC3 pro-
genitors in vivo. Hence, we cannot exclude a role of GM-CSF
on DC3s survival instead of differentiation. In addition, we
showed that GM-CSF drives DC3differentiation fromCD34+ um-
bilical cord HSPCs in vitro. This finding does not exclude that
other growth factors control DC3 development in vivo.
We aligned CD1c+CD14+ cells infiltrating breast tumor-drain-
ing lymph nodewith blood DC3s compared to cDC2s andmono-
cytes. Due to limited availability of healthy human lymph nodes,
we did not investigate if CD1c+CD14+ cells are infiltrating sec-
ondary lymphoid organs in homeostatic conditions. Blood
DC3s upregulate CCR7 upon TLR stimulation suggesting they
have a migratory potential. However, we did not investigate
whether lymph nodes DC3s originate from non-lymphoid periph-
eral tissues via lymphatic vessels or directly from blood.
A defining feature of cDCs lies in their ability to prime naı¨ve T
cells. We showed that DC3s can induce the proliferation of naı¨ve
T cell in a non-autologous priming context, i.e. the mixed leuko-
cyte reaction. The capability of DC3s to uptake, process and
present antigens by MHCI and MHCII molecules remains to be
addressed.
Our in vitro experiments showed that i) DC3s induce efficiently
TRM differentiation from naı¨ve CD8
+T cells and, ii) DC3 infiltration
correlates with TRM abundance in vivo. However, this does not
provide a direct evidence that DC3s control TRM specification
within tumor draining lymph nodes where they are likely to
interact with naı¨ve T cells. Indeed, we cannot rule out that, in
vivo, DC3s act selectively in the tissue to maintain TRM popula-
tions primed in lymph nodes by a different DC subtype. Further
studies will be needed to address how DC3s control CD8+ TRM
populations in vivo.STAR+METHODS
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Lead Contact
Additional information and request for resources and reagents should be directed to and will be made available by the Lead Contact,
Pierre Guermonprez (pierre.guermonprez@kcl.ac.uk).
Materials Availability
The reagents generated in this study will be made available on request, but we may require a payment and/or a completed Materials
Transfer Agreement if there is potential for commercial application.
Data and Code Availability
The scRNA-seq and the bulk RNA-seq datasets are deposited in the Genome Expression Omnibus under the SuperSeries accession
numbers GSE151095.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Human umbilical cord and adult blood
Human umbilical cord blood units were obtained from Anthony Nolan Cell Therapy Centre (ANCTC). Leukophoretic adult blood (buffy
coats or leukocyte cones) were obtained from healthy volunteers through NHS.
Clinical samples
Tumor-invaded lymph nodes (tdLN) and primary tumors were collected from luminal breast cancer submitted to surgical resection at
the Institut Curie Hospital (Paris, France), in accordance with institutional ethical guidelines. Patients’ clinical and pathologic char-
acteristics are summarized in Table S2.
Mice
NSG (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) mice were bred and maintained in specific pathogen-free animal facility in accordance with
institutional KCL guidelines. All procedures involving animals were conducted according to requirements of UK Animals (Scientific
Procedures) Act 1986.
METHOD DETAILS
Human blood and CD34+ progenitors
Peripheral blood mononuclear cells (PMBCs) were obtained by gradient centrifugation using Ficoll-Paque (GE Healthcare). Progen-
itor cells were enriched using CD34+ microbead isolation kit (Miltenyi).
Tumor cell lines
B16_CTRL, B16_huGM-CSF and B16_huFLT3L were generated by retroviral transduction of B16-F10 (C57BL/6 melanoma cell line)
with an empty pMX-IRES-GFP vector or coding for human GM-CSF and human Flt3L respectively. Tumor cell lines were cultured in
RPMI 1640 medium (Thermo Fisher) supplemented with 10% fetal bovine serum (FBS) (Thermo Fisher), penicillin-streptomycin
(Thermo Fisher) and b-mercaptoethanol (Thermo Fisher) (complete RPMI) and maintained at 37C and 5% CO2.e4 Immunity 53, 1–18.e1–e8, August 18, 2020
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Engineered B16-F10 cells were counted and resuspended in RPMI 1640 medium. NSG mice (8-12 weeks, males and females) were
injected intravenously with 106 B16-F10 at day 0. 108 human blood PBMCs were injected intravenously at day 7 and 8. Mice were
culled at day 9 and lungs were harvested.
Histology
Mouse lungswere fixedwith 1%PFA (Alfa Aesar) for 1hr at 4C,washed and incubated in 34%sucrose solution (Sigma-Aldrich) over-
night at 4C. Lungs were embedded in Cryomatrix (Thermo Fischer) and frozen for cryostat sectioning (9 mm-thick). Sections were
permeabilized using 0.5% saponin (Sigma-Aldrich), 2% BSA (Sigma-Aldrich), 1% FBS (Life Technologies) for 30 minutes at room
temperature. Sections were labeled overnight at 4Cwith mouse anti-human purified CD45 (HI30, Biolegend) followed by incubation
for 1hr at room temperature with goat anti-mouse Cy3 (Jackson laboratory). All sections were labeled with Hoechst (Molecular
Probes, Thermo Fisher) for nuclei staining 5 minutes at room temperature and mounted with Prolong diamond (Thermo scientific).
Slides were imaged using a SP5 (Leica) and analyzed with Fiji software.
Preparation of cell suspensions from lung mouse
Mouse lungs were harvested and transferred to 3ml digestion buffer (Hank’s Balanced Salt Solution (HBSS) with calcium and mag-
nesium (Thermo Fisher) and with 0.1 mg/ml of Liberase TL (Roche) and 0.02mg/ml DNase I (Thermo Fisher). Lungs were dissociated
using gentleMACS Octo Dissociator (Miltenyi) and incubated at 37C for 45 minutes. The cell suspension was passed through a cell
strainer (70mm, Corning) and red blood cells were lysed using ACK lysing buffer (Thermo Fischer). The absolute number of cells in the
resulting cell suspension was assessed using AccuCheck Counting Beads (Thermo Fisher) on BD FACSCanto II (BD Biosciences).
Stromal cell line maintenance
Mouse bone marrow-derived MS5 stromal cells engineered to express human membrane bound FLT3L alone (MS5_FL) or in com-
bination with SCF and soluble CXCL12 (MS5_FS12) or humanGM-CSF alone (MS5_GM) generated as previously described (Anselmi
et al., 2020). Stomal cell lines were cultured in IMDMmedium supplemented with 10% heat-inactivated FBS, penicillin/streptomycin,
50 mM b-mercaptoethanol (complete IMDM) and maintained at 37C and 5% CO2.
In vitro differentiation from CD34+ progenitors or blood phagocytes
For in vitro co-culture experiments with stromal cells, MS5_FL, MS5_FS12 and MS5_GM feeders were seeded at 104 cells/well den-
sity in a 96-well plate (Thermo Fischer) and maintained overnight at 37C and 5% CO2.
Total enriched-CD34+ progenitors and flow cytrometry-sorted progenitor subsets (GMDP, CDP and cMoP) were plated on top of
stromal cells, supplemented or not with 100ng/ml of recombinant human GM-CSF (Peprotech), for 14 days and 7 days, respectively.
Blood phagocytes subsets were flow cytometry-sorted and plated on MS5_GM for 2 days.
For bulk RNA sequencing analysis, total enriched-CD34+ progenitors were plated on top of MS5_FS12 feeders and with or without
100ng/ml of recombinant human GM-CSF (Peprotech). On day 5 and 10 of differentiation, half the medium was replaced with fresh
complete IMDM or complete IMDM containing 100ng/ml of recombinant human GM-CSF. Cells were collected at day 15.
All cells were collected with a solution of phosphate buffered saline (PBS) (GIBCO) 5mM EDTA (Thermo Fisher) at 4C for 10min.
In vivo conversion assay
PBMCs from healthy donors were stained and sorted as described previously. Blood cDC2 (105) and monocytes (33 105) were flow
cytometry-sorted and injected subcutaneously along with B16_huGM (105) in 200 mL of ice-cold Matrigel (BD Biosciences). Mice
were sacrificed at day 4 by cervical dislocation andMatrigel plugs were collected. Subcutaneous Matrigel plugs were recovered,
cut in pieces and incubated in HBSS (Life Technologies) 1% FBS, 0.37 U/ml Collagenase D (Roche), 10 mg/ml DNaseI (Roche) and
1mg/ml Dispase (Sigma-Aldrich) for 30 minutes at 37C. After digestion, plugs were smashed on a 70 mm strainer (Corning) and cells
were collected and resuspended in flow cytometry buffer for flow cytometry analysis.
Flow cytometry analysis
Cells were stained in flow cytometry buffer (PBS 5mMEDTA 1%BSA) according to antibody panels (Key Resources Table) for 30min.
Dead cells were stained using DAPI or Live/Dead Blue staining (Thermo Fischer). Lineage (Lin) included CD3, CD19, CD20, NKp46,
CD56, CD203c and CD66b, all conjugated with biotin. Multiparameter analysis was performed on LSRFortessa and Symphony (BD
Biosciences) flow cytometers and analyzed using FlowJo software (Tree Star). The flow cytometry-sort was performed on BD FACS
Aria II or BD FACS Aria Fusion at the Biomedical Research Centre (BRC) Flow Core Facility (Guy’s and St Thomas’ NHS Foundation
Trust and King’s College London).
Unsupervised clustering of flow cytometry data (Figure 1F) was performed using Self-Organizing Map clustering algorithm Flow-
SOM (Cytofkit R package). Data was then extracted as FCS files and further analyzed in FlowJo software.
Bulk RNA sequencing
For bulk sequencing of in vitro differentiated subsets, up to 100 flow cytometry-sorted cells from three individual donors were
collected directly in Lysis buffer (Takara Clontech, Cat# 635015) containing RNase inhibitors. RNaseq libraries were prepared onImmunity 53, 1–18.e1–e8, August 18, 2020 e5
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length cDNA was generated with a modified protocol of the SMARTseq v4 Ultra Low Input RNA Kit (Takara Clontech, Cat# 634891)
using poly dT primers and a template switching oligo. Full length cDNA was amplified using SeqAmp DNA Polymerase (Takara Clon-
tech, Cat# 638509). 12 ng of amplified cDNA from each sample was used to generate non-stranded RNA libraries using a modified
protocol of the Ovation Ultralow System V2 1-96 kit (NuGEN, Cat# 0347-A01). In brief, amplified cDNA was fragmented through son-
ication on Covaris E220 (Covaris Inc), repaired and polished followed by ligation of indexed adapters. Adaptor ligated cDNA were
pooled before final amplification to add flow cell primers. Libraries were sequenced on HiSeq2500 (Illumina Cambridge) for 100 cy-
cles PE in Rapid mode.
Bulk RNA sequencing data processing
The raw sequencing data was initially processed using open source, web-based platform Galaxy (version 18.05.rc1) (https://
usegalaxy.org). Reads were filtered for quality with more than 80% of the sequence having quality score > 33 using FastQC tool.
Mapping against reference genomewas performedwith Hisat2 to the hg38 human genome. Adaptor sequences were detected auto-
matically with TrimGalore!. Reads under 20bp were discarded. All processed sequencing files were imported in Partek Genomics
Suite software, version 7.0ª; 2017 (PGS), where they were processed further.
Primary data analysis and visualization
mRNAwas quantified using PGS built in RNA-seqworkflow. Normalizationmethod usedwas Reads Per Kilobase perMillionmapped
reads (RPKM) andmRNAwas quantified against RefSeq Transcripts 2018-11-20 database. Hierarchal clustering on average expres-
sion within the group was performed on all identified protein coding genes (19791 genes). Based on the CD14-CD1c+CD206+/ two
blue cluster similarity, they were both considered as cDC2-like cells and their datasets were merged for further analysis. The same
was done for the twomacrophage-like cells (gray and brown). Differentially expressed genes (Fold-Change%2 orR 2 and p value <
0.05) were determined using one-way ANOVA in all pairwise comparisons with three donors grouped and visualized as Volcano plots
in PGS. Individual samples were visualized via principal component analysis (PCA) using 500most variable genes, which were deter-
mined based on median absolute deviation (MAD). The expression patterns of selected gene lists were displayed in the form of heat-
maps, where rows and/or columns were ordered based on hierarchical clustering using Euclidean distance and average linkage in
Morpheus (Broad Institute; https://software.broadinstitute.org/morpheus/). A few gene names are depicted next to the heatmap.
Single-cell RNA sequencing
PBMCs from three healthy donors or human CD45+ cells isolated from metastatic mouse lungs were isolated as previously
described. Sorted cells from each donor were pooled together and CD1c+ and CD14+ cells were mixed at 80:20 ratio. 33 103 cells
from the resulting cell suspension were partitioned into an emulsion of nanoliter-sized droplets using a 10XGenomics Chromium Sin-
gle Cell Controller and RNA sequencing libraries were constructed using the Chromium Single Cell 30 Library & Gel Bead Kit v2 (10X
Genomics, Cat# PN-120237). Briefly, droplets containing individual cells, reverse transcription reagents and a gel bead were loaded
with poly(dT) primers that include a 16 base cell barcode and a 10 base uniquemolecular index (UMI). Reverse transcription reactions
were engaged to generate barcoded full-length cDNA followed by the disruption of emulsions using the recovery agent and cDNA
clean up with DynaBeads MyOne Silane Beads (Thermo Fisher Scientific, Cat# 37002D). Bulk cDNA was amplified, and indexed
sequencing libraries were constructed using the reagents from the ChromiumSingle Cell 30 v2 Reagent Kit. Libraries were sequenced
on NovaSeq 6000 Sequencing System (Illumina Cambridge).
Single-cell RNaseq data processing and analysis
Cell Ranger (version 2.1.1) (from 10x genomics) was used to process Chromium single cell 30 v2RNA-seq output files. First, we gener-
ated fastq files for the Read1 for cell barcode andUMI and Read2 for transcript applying cellranger mkfastq (with default parameters).
Second, we aligned the Read2 to the human reference genome GRCh38 using STAR (version 2.5.1) with cell ranger count (with
default parameters) (https://support.10xgenomics.com/single-cell-gene-expression/software/pipelines/latest/using/mkfastq).
Further analysis was performed using Seurat package (version 2.3.4) in R (version 3.4.0) (Butler et al., 2018). Before performed anal-
ysis, we applied the following filtering step: only genes expressed in 3 or more cells have been preserved and cells with less 200
unique genes and more than 4000 unique expressed genes were discarded (as they are potentially cells doublets). After filtering
step, we used an expression matrix resulting in 14933 genes across 1622 cells (among 1625 cells) for the rest of the analysis. The
matrix was normalized using genes expression values for each cell were divided by the total number of transcripts and multiplied
by median of UMI counts. Then, these values were natural log-transformed before downstream analysis. For dimensionality reduc-
tion analysis, we first identified 3288 genes as highly variable genes across the single cells (cutoff value for dispersion = 0.5; cutoff
value for average expression = 0). PCA performed using the variable genes as input and determined 10 PCs as significant PCs. These
principal components were used as input for t-Distributed Stochastic Neighbor Embedding (tSNE) (van der Maaten, 2008). We used
the shared nearest neighbor (SNN) modularity optimization-based clustering algorithm from the Seurat package (FindClusters func-
tion with default parameters) to identify the clusters of cells, following by Clustree analysis (clustree R package, version 0.2.2) by
changing the resolution parameters from 0 to 2. Finally, we kept a resolution parameter at 0.8 and defined distinct 9 clusters. After
controlling expression of some quality control genes, we excluded clusters E, F, G, H and I as contamination. Finally, we identified 4
relevant clusters. We identified cell specific marker by comparing cells in a specific cluster with cells in all other clusters using Fin-e6 Immunity 53, 1–18.e1–e8, August 18, 2020
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performed using Seurat package.
Signature expression analysis
Single-cell RNA sequencing matrix for clusters A, B, C and D was created with gene signatures from Villani et al. (2017). Signatures
were defined as mean expression of discriminative markers for cDC2s and DC3s among lin-CD14- cells (cDC2 enriched and DC3
enriched, respectively) and of discriminative markers for CD14+ monocytes within lin-CD14+/ and/or CD16+/ monocytes (CD14+
mono enriched). The average expression of signature genes for each cell was calculated and plotted as a violin plot using R package
ggplot2 (version 3.1.0).
Gene set enrichment analysis
To statistically evaluate the enrichment of previously reported gene signatures (Gene Sets) (Hombrink et al., 2016; Kumar et al., 2017;
Savas et al., 2018; Villani et al., 2017) in our dataset, we used pairwise comparisons using the gene set enrichment analysis (GSEA)
(Subramanian et al., 2005) method from the Massachussets Institute of Technology (https://www.broadinstitute.org/gsea). GSEA
tests the relative position of a collection of genes (Gene Set) within an independent, ranked dataset (GeneList). Statistical analysis
was performed by evaluation of nominal p value and false discovery rate (q value) based on 1,000 random permutations. Results
were considered significant when the p value was below 0.05 and when the q value was below 0.25 (false discovery rate below
25%) accordingly to the recommendation from the software developers. For each pairwise comparison, the GSEA output can be
represented as a bar code where each bar corresponds to the projection of one Probe Sets of the Gene Sets on the list of all the
Probe Sets of the gene chips ranked from those having a high signal in one cell population (represented in red) to those having a
high signal in the other cell population (represented in blue). Each bar code can be characterized by two parameters. The normalized
enrichment score (NES) represents the number and differential expression intensity of the genes enriched in the corresponding cell
subset. The NES is positive if the Gene Set is enriched in the first cell population and negative if it is enriched in the second cell pop-
ulation. The false discovery rate (FDR) statistical value (q) represents the likelihood that the enrichment of the Gene Set represents a
false positive finding (for example if q = 0.25, 25% of the Gene Sets found enriched can be false positives). An absolute value of the
NES below or around 1 means no enrichment as confirmed with associated q-values above 0.25.
To simultaneously visualize pairwise comparisons of transcriptomes from cord blood-derived DC2s (light and dark blue) DC3s (or-
ange) and macrophages (gray and brown), the BubbleMap module of BubbleGum (Spinelli et al., 2015) was used. Results were
considered significant when the p value was below 0.05 and the FDR (false discovery rate, q) value was below 0.25. The BubbleGum
was performed using previously published gene signatures of pairwise comparison between DC2s and DC3s and DC3s and CD14+
monocytes (Villani et al., 2017).
Human tissue processing and cell suspension
Tumor-draining lymph nodes (tdLN) and primary tumors were collected in CO2 independentmedium (GIBCO; Cat# 18045-054) within
few hours after the primary surgery. Tissue were cut into small fragments and submitted to enzymatic digestion using 0.1 mg/ml of
Liberase TL (Roche) and 0.1 mg/ml of DNase (Roche) for 30 min. Cells were filtered on 40-mm cell strainer (BD), washed using CO2
independent medium (GIBCO; Cat# 18045-054) containing 0.4g/ml of human albumin and resuspended for cell counting.
Cell sorting of myeloid subsets from patients’ tdLN for RNA sequencing
After tissue processing, cells obtained from tdLN were submitted to myeloid cells enrichment accordingly to (Durand and Segura,
2016) prior flow cytometry-sorting. In brief, T and B lymphocytes, NK cells, erythrocytes and myelomonocytic cells were depleted
using monoclonal antibodies against: CD3, CD19, CD56, CD235a and CD15, respectively. Subsequently, cell suspensions were
stained for 30 min with antibody-conjugated as the following: HLA-DR, CD11c, CD14, CD1c, CD304, CD1a, CD206, CD141. Around
1,000 cells of each DC subset were sorted by flow cytometry using BD FACS ARIA II cell sorter, (purity > 98%). Cells were centrifuged
and lysed with TCL buffer (QIAGEN) containing 1% of beta-mercaptoethanol before storage at80C. RNA were extracted and iso-
lated using the Single Cell RNA purification kit (Norgen, Cat#51800) according to the manufacturer’s instructions and the RNA integ-
rity number was evaluated with an Agilent RNA 6000 pico kit.
LEGENDplexTM assay
PBMCs and in vitro generated cells were stained and sorted as described previously. In total 3 3 105 of blood cell subsets (cDC2,
DC3 and Mono) or 105 in vitro generated cells (cDC2-, DC3 and Macro-like) were flow cytometry-sorted and cultured with TLR ag-
onists cocktail containing 25 mg/ml Poly I:C (InvivoGen, Cat# 31852-29-6), 1 mg/ml R848 (InvivoGen, Cat# 144875-48-9) and 10ng/ml
LPS (Sigma-Aldrich, Cat# L2630) for 16 h. Culturing supernatants were collected and stored at20C until the LEGENDplexTM assay
execution day. LEGENDplex Human Macrophage/Microglia Panel (13-plex) with V-bottom Plate (Biolegend Cat# 740503) and Hu-
man Proinflammatory Chemokine Panel (13-plex) with V-bottom Plate (Biolegend Cat# 740003) was used according to manufac-
turer’s instructions. In short, samples and standards were thawed and plated with capture beads and incubated for 2 h. Plate
was then washed, and Detection Antibodies were added. After 1 h incubation SA-PE was added and incubated for 30 min. Samples
were acquired on BD FACSCanto II. Samples were analyzed using LEGENDplexTM Data Analysis Software.Immunity 53, 1–18.e1–e8, August 18, 2020 e7
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PBMCs and in vitro generated cells were stained and flow cytometry-sorted as described previously. 104 mononuclear phagocytes
were cultured with TLR agonists cocktail containing 25 mg/ml PolyI:C, 1 mg/ml R848 and 10 ng/ml LPS for 16 h. T cells were isolated
from fresh or frozen PBMCs using Naive Pan T Cell Isolation Kit (Miltenyi, Cat# 130-097-095) and 105 cells were plated on top of
mononuclear phagocytes in presence of CytoStim (Miltenyi, Cat# 130-092-172), according tomanufacturer’s instructions. For mixed
leukocyte reaction (MLR) experiments, isolated Naive Pan T cells were labeled with Cell Tracer Violet (CTV) (Thermo Fischer, Cat#
C34557) as per manufacturer’s instructions and cultured with flow cytometry-sorted DCs without CytoStim. At day 5, cells were
collected and stained for extracellular and intracellular marker expression and analyzed using BD LSRFortessa. For intracellular
staining, fixation and permeabilization were performed using BD Cytofix/Cytoperm solution (BD Biosciences, Cat# 554714) accord-
ing to manufacturer’s instructions.
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical analysis was performed using Prism 8.3 (GraphPad Software Inc., USA). When two experimental groups were compared,
non-parametric Mann-Whitney test was used. When three or more groups were compared, statistically significant differences be-
tween means were determined using the one-way or two-way analysis of variance (ANOVA) method. A p value of less than 0.05
was considered as significant.e8 Immunity 53, 1–18.e1–e8, August 18, 2020
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Figure S1. Related to Figure 1 
(A) Gating strategy used to identify CD14+/- and/or CD1c+/- cells for scRNAseq analysis. In 
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healthy donors were sorted separately and then pooled together in a 20:80 ratio of monocytes 
versus CD1c+ cells. 3000 cells from the obtained suspension were loaded into a Chromium 
10X chip for droplet-based single-cell isolation. (B) Violin plots illustrating expression 
probability distributions across clusters of lineage-specific markers used to discriminate 
CD33-expressing myeloid clusters (A, B, C and D) from additional contaminating subsets 
(clusters E, F, G, H and I). (C) Violin plots illustrating expression probability distributions of 
representative DEG across clusters A, B, C and D (226 total DEG). (D) Heat map displaying 
relative expression of markers detected by flow cytometry on subsets 1, 2, 3 and 4 identified 
by FlowSOM analysis. (E) Gating strategy used to define the blood cell subsets sorted for the 
bulk RNAseq. (F) PCA of DEG for bulk sequenced mononuclear phagocyte populations. 
Displayed principal components 1 versus 3 and 2 versus 3. (G) Volcano plots showing the 
DEG between bulk sequenced DC3 as compared to monocytes or both CD5+ and CD5- cDC2 
cells. Genes with Log2(FC)>±2 and FDR adjusted p value less than 0.05 were considered 
significant. Genes in bold are differentially expressed in CD5+ and CD5- cDC2s when 
compared to DC3s. (H) Graphical summary of the blood CD1c+ and monocyte cells. 
 
Figure S2. Related to Figure2 
(A) Full gating strategy used to define macrophages, cDC1s, CD5+ cDC2s and CD14+ DC3s in 
human breast cancer primary tumors. (B) Histograms showing the expression of CD5, CD1c, 
CD88, CD14, HLA-DR and XCR1 in macrophages, cDC1s, CD5+ cDC2s, CD14+ DC3s and 
CD5-CD14-CD1c+ in human breast cancer primary tumors. (C) Backgating of the CD14+ DC3s 
in human breast cancer primary tumors. (D) Quantification of the CD1c+CD14+ cells in the 





Figure S3. Related to Figure 3 
 
(A) Schematic of plasmids used to generate B16 melanoma cell lines expressing human 
FLT3L (B16_huFL) and human GM-CSF (B16_huGM). The production of human cytokines 
was validated by ELISA performed on the supernatant of cultured cells as well as on the 
serum of tumor-bearing mice. The expression of a reporter gene (GFP) was assessed by flow 
cytometry. (B) Gating strategy used to define macrophages, CD3+ T cells and huCD45+HLA-
DR+CD88-CD141- cells in B16_huGM metastatic lung at day 9. (C) Bar graph summarizing 
the frequency of total human CD45+ cells isolated from B16_CTRL, B16_huFLT3L or 
B16_huGM metastatic lung at day 9 (n=3). (D) Backgating of the CD1c+CD163+CD5- and 
CD1c+CD14+CD5- in the B16_huGM metastatic lung (related to fig. 3C). (E) Histograms 
showing the expression of CD11c and FcεRI on cDC2 (blue) and DC3 (orange) and CD3+ T 
cells (grey) (related to fig. 3C). (F) Pie chart summarizing the average frequency of each 
subset within HLA-DR+ cells. (G) Gating strategy used to define CD14+/- and/or CD1c+/- cells 
for scRNAseq analysis. Single cells were isolated using a droplet-based approached and 
sequenced. Dimensionality reduction of scRNA-seq data was performed using UMAP. 
Clusters 0 and 1 were identified using SNN clustering algorithm. Each dot represents an 
individual cell (n=293). (H) Volcano plots showing the DEG between clusters 0 and 1 
identified in (F). Genes with Log2(FC)>±0.5 and FDR adjusted p value less than 0.05 were 
considered significant. (I) Violin plots illustrating expression probability distributions across 
the two clusters of representative genes (out of 112 differentially expressed genes). (J) 
Expression distribution across clusters 0 and 1 of gene signatures identified in Villani et al., 
2017. Signatures were defined as mean expression of discriminative markers for DC3 and 
CD14+ monocytes within the lin-CD14+/- cells (Villani et al., 2017). 
  
Figure S4, related to Fig.3 
(A) Flow cytometry analysis of flow cytometry-sorted cDC2, DC3, CD88+CD14+ 
monocytes and all CD14+ cells after 2 days of culture with 100ng/ml recombinant GM-CSF 
and 50ng/ml recombinant IL-4. Bar graphs show the frequency of output cells within the total 
live cells (n=3 healthy donors). (B) Experimental strategy for in vivo plug. flow cytometry-
sorted blood myeloid cells were injected subcutaneously along with B16-huGM in a 
basement membrane matrix (Matrigel) preparation.  (C) Flow cytometry analysis of flow 
cytometry-sorted cDC2 and CD88+CD14+ monocytes after 4 days in B16-huGM containing 
Matrigel plug. Bar graphs show the frequency of output cells within the total huCD45+ cells 
(n=4-5 healthy donors).  
Figure S5. Related to Figures 4 and 5 
(A) Full gating strategy CD1c+CD14+ and the CD1c+CD14-  after coculture of human cord 
blood-derived CD34+ with MS5_FS12. (B) Gating strategy used to flow cytometry-sort for 
bulk RNAseq analysis of in vitro-differentiated macrophages (brown), monocytes (grey), 
cDC1s (red), CD206 +/- cDC2s (blue and turquoise) and DC3s (orange) after coculture of 
human cord blood-derived CD34+ with MS5_FS12 in presence of GM-CSF. (C) Heat map of 
discriminative gene sets based on Signal to noise ratio across the different cell types for 
CD14-CD1c+CD206+/- cDC2-like cells (blue and turquoise), CD14+CD1c+ DC3-like cells 
(orange), CD14+CD16+/-CD1c- macrophage-like cells (grey and brown).  (D) Volcano plots 
showing the DEG between in vitro generated cDC2 cells cocultured with MS5_FS12+recGM 
(blue and turquoise circles) as compared to cDC2-like cells cocultured with MS5_FS12 (blue 
and turquoise squares). Genes with Log2(FC)>±2 and FDR adjusted p value less than 0.05 
were considered significant. (E) Heat map showing the relative expression of markers used 
for subset identification in Fig. 1. (F) Quantification of CCL2 secreted by cDC2-, DC3- and 
Macro-like in vitro generated cells in response to overnight stimulation with a cocktail of 
TLR agonists (n=3-8; line represent median; *p<0.05, one-way ANOVA test). (G) Gating 
strategy defining CDP, cMoP and GMDP within CD34+ cord blood derived HSPC. (H) 
Gating strategy to identify CD14+CD16+ macrophages (brown), CD14-CD15+ granulocytes 
(purple), CD14+CD1c+ DC3 (orange), CD14-CD1c+Clec9A- cDC2 (blue) and CD14-
CD1c+Clec9A+ cDC1 (red) in 7 days cultures of CDP, cMoP and GMDP with MS5_FS12 
and MS5_GM. (I) Bar graph summarizing the number of wells resulting in differentiated 
cells from single CD34+CD38+CD45RA+CD123-CD64- cells cocultured MS5_FS12+recGM-
CSF or MS5_GM and percentage of cloning efficiency. n/a (not available) corresponding to 
empty wells at the read out. 
 
  
Figure S6 related to Fig. 6 
(A) Flow cytometry analysis of flow cytometry-sorted cDC1, cDC2, DC3 and CD88+CD14+ 
monocytes after 16 hours of activation with TLR agonists (25µg/ml PolyI:C, 1µg/ml R848 and 
10ng/ml LPS). Bar graphs show the frequency of output cells within the total live cells (n=6 
healthy donors). (B) Volcano plots showing the DEG between bulk sequenced TLR agonist 
stimulated cDC2 as compared to not stimulated DC3. Genes with Log2(FC)>±2 and FDR 
adjusted p value less than 0.05 were considered significant. (C) Heat map showing the relative 
gene expression of chemokines in TLR agonist cocktail stimulated (25µg/ml PolyI:C, 1µg/ml 
R848 and 10ng/ml LPS) or not stimulated mononuclear phagocyte populations. (D) 
Quantification of chemokines secreted by cDC2, DC3 and monocytes in response to overnight 
stimulation with a cocktail of TLR agonists (n=9 healthy donors; line represent median; 
*p<0.05, **p<0,01, ****p<0.0001, one-way ANOVA test). (E) Heat map showing the relative 
gene expression of cytokines in TLR agonist cocktail stimulated or not stimulated mononuclear 
phagocyte populations. 
Figure S7, related to Fig. 7 
A) Gating strategy used to flow cytrometry-sort blood cDC2, DC3 and monocytes for T cell 
coculture. (B) and (D) Representative flow cytometry plots and quantification of CD4+ and 
CD8+ naïve T cells cultured for 5 days with flow cytometry-sorted blood cDC2, DC3 or 
CD14+ monocytes after overnight activation with TLR agonists (25µg/ml PolyI:C, 1µg/ml 
R848 and 10ng/ml LPS) in the presence of a synthetic superantigen (Cytostim). Absolute 
numbers and frequencies of CD45RO+ differentiated T cells (B), cytokines-producing 
activated T cells (D). (n=5 healthy donors in 5 independent experiments, line represent 
median; *p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001; one-way ANOVA test). (C) 
Flow cytometry plots of CTV-labeled CD4+ and CD8+ naïve T cells cultured for 5 day with 
flow cytometry-sorted DC1, cDC2, DC3 and macrophages generated in vitro, on MS5-FL for 
cDC1 and cDC2 or MS5-GM for DC3 and macrophages, after overnight activation with TLR 
agonists (25µg/ml PolyI:C, 1µg/ml R848 and 10ng/ml LPS) in the presence of a synthetic 
superantigen (Cytostim). CTV dilution and expression of CD45RA and CD45RO are shown 
(n=1 in 1 experiment).  (E) Representative flow cytometry plots and quantification of CTV-
labelled CD8+ naïve T cells cultured for 5 days with flow cytometry-sorted blood cDC2, DC3 
or CD14+ monocytes after overnight activation with TLR agonists (25µg/ml PolyI:C, 1µg/ml 
R848 and 10ng/ml LPS). Proliferation (CTV dilution) and CD103 expression on CD8+ T are 
shown. (n=3 healthy donors in 3 independent experiments, line represent median; **p<0.01 
and ***p<0.001; one-way ANOVA test). (F) Flow cytometry plots showing CD103 
expression on CD8+ naïve T cells cocultured with flow cytometry-sorted blood DC3 after 
overnight activation with TLR agonists (25µg/ml PolyI:C, 1µg/ml R848 and 10ng/ml LPS) in 
the presence of 10μg/ml of neutralizing antibodies or their respective isotype controls (n=1 
healthy donor in 1 experiment). (G) Gating strategy used to flow cytometry-sort CD103- and 
CD103+CD8+ T cells cultured for 5 days with flow cytometry-sorted blood DC3 after 




Table S2: Clinical data for the patients with primary breast tumors and invaded lymph nodes, 
Related to Figures 2 and 7. 
Code patient Age HISTO. GRADE SIZE pTNM ER (%) PR (%) HER2 Ki67 (%) 
Primary tumor 1 57 Ductal 3 32 mm pT2 N0 100 15 neg 60
Primary tumor 2 71 Ductal 2 18 mm pT1c N0 90 10 neg 15
Primary tumor 3 72 Lobular 2 5 mm pT2 N1a 80 80 neg 20
Primary tumor 4 41 Mixte 2 4 nodules (5 to 30 mm) and multiples satellite nodules (1 to 4 mm)pT2m N1 70 60 N/A 80
Primary tumor 5 55 Ductal 2 3 to 16 mm pT1cm N1 95 1 neg 15
Primary tumor 6 76 Ductal 3 22 mm pT2 N1 100 0 neg 35
Primary tumor 7 61 Ductal 3 32 x 25 mm pT2 N0 100 60 neg 40
Primary tumor 8 70 Ductal 3 30 + 26 + 18 mm pT2m N1 100 80 N/A 30
Primary tumor 9 55 Lobular 3 25 mm pT2m N0 70 5 neg 35
Primary tumor 10 59 Ductal 2 15 mm pT1c N1 0 0 pos 25
Primary tumor 11 48 Lobular 2 60 mm and multiples satellite nodules (1 to 5 mm) pT3 N1 100 50 neg 35
Primary tumor 12 58 Ductal 3 26 x 22 mm + one satellite nodule (2 mm) pT2 N0 95 85 neg 25
Primary tumor 13 84 Ductal 1 22 mm pT2 N2 100 80 neg 18
Primary tumor 14 82 Ductal 2 12 + 16 mm pT1c N1 100 10 neg 5
Primary tumor 15 37 Multifocal 2 35 + 22 + 15 + 6 mm pT2 N1 100 5 neg 25
Primary tumor 16 70 Ductal 2 21 mm pT2m N0 100 100 neg 15
Primary tumor 17 77 Carcinoma 2 65 mm pT3 N2 100 80 neg 2
Primary tumor 18 46 Ductal 3 40 mm pT2 N1 50 80 neg 60
Primary tumor 19 54 Mixte 3 25 mm pT2 N0 100 N/A neg 20-25
Primary tumor 20 63 Ductal 2 40 mm  pT2 N1a 100% 10% neg 50
Primary tumor 21 55 Lobular 2 32 mm pT2 N0 100 10 neg 40
Primary tumor 22 81 Lobular 2 60 mm pT3 N3a 100 80 neg 17
Primary tumor 23 48 Lobular 2 6 mm pT3 N1a 70 40 N/A 10
Primary tumor 24 40 Ductal 2 13 mm pT1c N0 100 90 neg 5
Primary tumor 25 51 Ductal 3 53 mm pT3 N0 100 0 neg 30
Primary tumor 26 54 Ductal 2 16 mm pT1c N0 80 10 neg 5
Primary tumor 27 62 Ductal 2 17 mm pT1c N1 95 85 neg 22
Primary tumor 28 63 Ductal 2 40 mm pT2 N1a 100 10 neg 50
Invaded lymph node 1 52 Ductal 2 17 mm pT1c  100 100 neg 11
Invaded lymph node 2 76 N/A 3 32 mm pT2N2 100 10 neg 30
Invaded lymph node 3 61 Ductal 3 25 mm pT2N1a 5 0 pos 60
